GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Diagnostic Molecular Pathology, Ovid Technologies (Wolters Kluwer Health), Vol. 18, No. 3 ( 2009-09), p. 144-149
    Type of Medium: Online Resource
    ISSN: 1052-9551
    RVK:
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2009
    detail.hit.zdb_id: 2045341-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: British Journal of Haematology, Wiley, Vol. 144, No. 3 ( 2009-02), p. 358-366
    Abstract: Heat shock protein 90 (HSP90) is a molecular chaperone that stabilizes critical client proteins in multiple cancers. Gene expression profiling was utilized to characterize HSP90 isoform expression in primary human diffuse large B‐cell lymphomas (DLBCLs). HSP90 α and β isoforms were differentially expressed in subsets of tumours defined by their transcriptional profiles. Thereafter, we assessed the activity of the HSP90 inhibitor, IPI‐504, in an extensive panel of DLBCL cell lines. IPI‐504, which interacts with the conserved ATP‐binding site in both HSP90 isoforms, inhibited proliferation and induced apoptosis in the majority of DLBCL cell lines at low micromolar concentrations. IPI‐504‐sensitive cell lines expressed high levels of the HSP90 client protein, pAKT, and exhibited dose‐dependent decreases in pAKT levels following IPI‐504 treatment and significantly reduced proliferation following AKT RNAi. Furthermore, the combination of low‐dose ( 〈 1 μmol/l) IPI‐504 and the AKT/Pi3K pathway inhibitor, LY24009, was synergistic in IPI‐504‐sensitive DLBCL cell lines. Low‐dose IPI‐504 was also synergistic with the chemotherapeutic agent, doxorubicin. The HSP90 inhibitor IPI‐504 warrants further investigation in DLBCL alone and in combination with identified client protein inhibitors and active chemotherapeutic agents.
    Type of Medium: Online Resource
    ISSN: 0007-1048 , 1365-2141
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 1475751-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Proceedings of the National Academy of Sciences ; 2007
    In:  Proceedings of the National Academy of Sciences Vol. 104, No. 32 ( 2007-08-07), p. 13134-13139
    In: Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 104, No. 32 ( 2007-08-07), p. 13134-13139
    Abstract: Classical Hodgkin lymphomas (cHLs) contain small numbers of neoplastic Reed–Sternberg (RS) cells within an extensive inflammatory infiltrate that includes abundant T helper (Th)-2 and T regulatory (T reg ) cells. The skewed nature of the T cell infiltrate and the lack of an effective host antitumor immune response suggest that RS cells use potent mechanisms to evade immune attack. In a screen for T cell-inhibitory molecules in cHL, we found that RS cells selectively overexpressed the immunoregulatory glycan-binding protein, galectin-1 (Gal1), through an AP1-dependent enhancer. In cocultures of activated T cells and Hodgkin cell lines, RNAi-mediated blockade of RS cell Gal1 increased T cell viability and restored the Th1/Th2 balance. In contrast, Gal1 treatment of activated T cells favored the secretion of Th2 cytokines and the expansion of CD4 + CD25 high FOXP3 + T reg cells. These data directly implicate RS cell Gal1 in the development and maintenance of an immunosuppressive Th2/T reg -skewed microenvironment in cHL and provide the molecular basis for selective Gal1 expression in RS cells. Thus, Gal1 represents a potential therapeutic target for restoring immune surveillance in cHL.
    Type of Medium: Online Resource
    ISSN: 0027-8424 , 1091-6490
    RVK:
    RVK:
    Language: English
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date: 2007
    detail.hit.zdb_id: 209104-5
    detail.hit.zdb_id: 1461794-8
    SSG: 11
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 2539-2539
    Abstract: Translocations of the mixed lineage leukemia (MLL) gene on chromosome 11q23 are found in over 70% of infant leukemias and associated with a poor prognosis. MLL translocations generate a new chimeric gene, in which N-terminal portion of MLL is fused to C-terminal sequence from multiple different partners. Given the variety of MLL fusion partners, molecular techniques such as FISH or Southern blotting are not able to detect all genetic abnormalities involving MLL. In addition, results from these time-consuming techniques are not always available at initial diagnosis. To identify molecular markers of MLL translocation that might be used in rapid diagnostic assays, we first compared the transcriptional profiles of primary precursor B cell acute lymphoblastic leukemias (ALLs) with and without MLL translocations. Galectin-1 (Gal1) transcripts were significantly more abundant in MLL-rearranged ALLs (MLL-ALL) from two extensive and independent datasets. Consistent with these findings, Gal1 protein was significantly more abundant in MLL-ALL cell lines than in non-MLL ALL lines by western blotting. These observations were of interest because Gal1 is a secreted immunoregulatory glycan-binding protein that induces the apoptosis of cytotoxic T cells and T helper1 cells and fosters an immunosuppressive tumor microenvironment. To assess the diagnostic utility of Gal1 expression in identifying the MLL-ALL subtype, we performed Gal1 immunostaining on a large series of primary ALLs with known MLL status. All 10 MLL-rearranged precursor-B ALLs had abundant Gal1 expression (10/10, 100%); in marked contrast, only 1 of 38 pre-B ALLs without a cytogenetically detectable MLL translocation expressed Gal1 (3%), p & lt;0.001. Since intracellular flow cytometry is routinely used in the diagnostic evaluation of ALL, we evaluated Gal1 expression in ALL subtypes with a recently developed Gal1 monoclonal antibody and intracellular flow cytometry. With this technique, Gal1 protein expression was high in MLL-ALL cell lines and low/undetectable in ALL lines without the MLL translocation. Since deregulated gene expression in MLL-rearranged leukemias may be related to the altered histone methyltransferase activity of MLL fusion protein complex, we analyzed histone H3 lysine 79 (H3K79) dimethylation in the Gal1 promoter region using chromatin immunoprecipitation. Gal1 promoter H3K79 dimethylation 5 fold higher in the MV-4-11 cell line bearing MLL-AF4 fusion was ≈ gene than in a pre-B ALL line without the MLL translocation, suggesting that this epigenetic modification may be a mechanism for Gal1 overexpression in MLL. We conclude that: Gal1 is specifically overexpressed in MLL-ALLs compared to non-MLL ALLs; Gal1 overexpression is likely driven by the altered histone methyltransferase activity of the MLL fusion protein complex; and 3) Gal1 is a promising diagnostic marker in these MLL-ALLs.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 469-469
    Abstract: Primary Hodgkin lymphomas (HL) contain small numbers of neoplastic Reed-Sternberg (RS) cells within an extensive host inflammatory infiltrate, which includes few cytotoxic T-cells. The lack of an effective host anti-tumor response prompts speculation regarding the mechanisms that HL RS cells use to evade immune surveillance. To identify novel HL-specific T-cell inhibitory molecules, we compared the gene expression profiles of a series of HL and diffuse large B-cell lymphoma (DLBCL) cell lines. The HL cell lines overexpressed galectin-1 (GAL1), a carbohydrate-binding lectin that selectively induces the apoptosis of cytotoxic T cells. GAL1 mRNA abundance was 5- to 33- fold higher in HL cell lines than in DLBCL lines. GAL1 protein expression was also uniformly high in HL cell lines and low or undectable in DLBCL lines by western blotting. Immunohistochemical staining of primary tumors revealed abundant GAL1 expression in HL RS cells whereas DLBCLs were uniformly negative. To elucidate the mechanisms responsible for GAL1 over expression in HL, we analyzed the GAL1 locus and identified a candidate AP1 enhancer element 1.5 kb downstream of the GAL1 transcription start site. The predicted enhancer element increased the expression of a reporter gene (luciferase) 5-fold in a HL cell line but had no effect in either a DLBCL or fibroblast cell line. In electrophoretic mobility studies, AP1 bound to the predicted GAL1 enhancer element in a cell-type specific manner. In addition, mutation of the AP1 binding site in the GAL1 enhancer abolished its activity. Since the AP1 components, cJUN and JUN-B, are known to be overexpressed in HL, we analyzed cJUN and JUN-B copy numbers and transcript abundance in the HL cell lines using 100K high-density SNP arrays and oligonucleotide RNA microarrays. We found increased copy numbers of cJUN and/or JUN-B in all HL cell lines tested and confirmed these findings using fluorescence in situ hybridization (FISH). Increased cJUN and JUN-B copy numbers were associated with significantly higher transcript abundance in the HL cell lines. In additional functional assays, we confirmed previous reports that recombinant GAL1 induced the apoptosis of CD3+ PHA-stimulated lymphoblasts in a dose- and time-dependent manner. Taken together, these studies indicate that HL RS cells selectively over express GAL1, at least in part, via AP1-mediated induction of the GAL1 enhancer. Given the profound effects of GAL1 on cytotoxic T cells, RS-specific expression of GAL1 likely inhibits the host anti-tumor response in HL.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...